Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SITAGLIPTIN PHOSPHATE MONOHYDRATE CRS (120 MG)

SITAGLIPTIN PHOSPHATE MONOHYDRATE CRS (120 MG)

654671-77-9

DISCOVER
GEFITINIB CRS (110 MG)

GEFITINIB CRS (110 MG)

184475-35-2

DISCOVER
BUSERELIN FOR NMR IDENTIFICATION CRS (2 MG)

BUSERELIN FOR NMR IDENTIFICATION CRS (2 MG)

68630-75-1

DISCOVER
SODIUM AMINOSALICYLATE DIHYDRATE FOR EQUIPMENT QUALIFICATION

SODIUM AMINOSALICYLATE DIHYDRATE FOR EQUIPMENT QUALIFICATION

205-091-2

DISCOVER
PYRANTEL IMPURITY D CRS (20 MG)

PYRANTEL IMPURITY D CRS (20 MG)

4271-96-9

DISCOVER
SCHISANDRIN CRS (15 MG)

SCHISANDRIN CRS (15 MG)

7432-28-2

DISCOVER
ALVERINE IMPURITY C CRS (40 MG)

ALVERINE IMPURITY C CRS (40 MG)

NA

DISCOVER
METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) CRS (

METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) CRS (

25086-15-1

DISCOVER
METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) CRS (

METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) CRS (

25086-15-1

DISCOVER
ZOPICLONE IMPURITY B CRS (20 MG)

ZOPICLONE IMPURITY B CRS (20 MG)

NA

DISCOVER
ESTRADIOL VALERATE FOR SYSTEMSUITABILITY CRS (15 MG)

ESTRADIOL VALERATE FOR SYSTEMSUITABILITY CRS (15 MG)

979-32-8

DISCOVER
TACALCITOL IMPURITY A CRS (0.001 MG)

TACALCITOL IMPURITY A CRS (0.001 MG)

1294517-97-7

DISCOVER